TY - JOUR
T1 - Monitoring molecular response in chronic myeloid leukemia
AU - Cortes, Jorge
AU - Quintás-Cardama, Alfonso
AU - Kantarjian, Hagop M.
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/3/15
Y1 - 2011/3/15
N2 - Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression-free survival, and event-free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described.
AB - Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression-free survival, and event-free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR-ABL1 transcript levels and caveats of molecular monitoring are also described.
KW - BCR-ABL
KW - chronic myeloid leukemia
KW - imatinib
KW - molecular response
KW - tyrosine kinase inhibitor
UR - http://www.scopus.com/inward/record.url?scp=79952381341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952381341&partnerID=8YFLogxK
U2 - 10.1002/cncr.25527
DO - 10.1002/cncr.25527
M3 - Review article
C2 - 20960522
AN - SCOPUS:79952381341
SN - 0008-543X
VL - 117
SP - 1113
EP - 1122
JO - Cancer
JF - Cancer
IS - 6
ER -